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Like sirolimus, everolimus is an inhibitor of mTOR (mammalian target of rapamycin), used as an
immunosuppressant in solid organ transplantation and as an antineoplastic agent. Its usage increases.
Many cases of sirolimus-induced hypersensitivity pneumonitis were reported. To our knowledge only
four cases of everolimus-associated interstitial pneumonitis have been reported in transplant recipients,
three in heart and the other in kidney transplantation, with a favourable outcome after discontinuation.
We report herein three cases of hypersensitivity pneumonitis due to everolimus.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Everolimus is an immunosuppressive agent belonging to the
mTOR inhibitors, used in solid organ transplantation in order to
prevent graft rejection. It is also used as an investigational anti-
neoplastic agent usedmainly for the treatment ofmetastatic kidney
carcinomas. Its use increases progressively. Many cases of pneu-
monitis were described as associated to another mTOR inhibitor,
sirolimus,5–14 but not to everolimus. Main side effects of ever-
olimus1 are hematological (leukopenia, neutropenia, lymphopenia,
thrombocytopenia), metabolic (dyslipidaemia), renal (renal insuf-
ﬁciency), hepatic (elevation of liver enzymes, cholestasis). We
report herein three cases of hypersensitivity pneumonitis due to
everolimus in three patients.1.1. Case 1
A 62-year-old patient was admitted for a dyspnea since 15 days.
He had displayed an adenocarcinoma of the left kidney diagnosed
in 2003, initially treated by widened nephrectomy. In 2005,
pulmonarymetastases were treated by surgery, and retroperitoneal
localizations were treated with interferon alpha for 5 months. Herax, Service de pneumologie,
r).
All rights reserved.received then the oral anti-angiogenic sunitinib because of
pulmonary progression. From March 5th 2005, the patient was
treated by 10 mg/d of everolimus as a third line therapy in the
frame of a clinical trial. Other treatments were: L-thyroxine, man-
idipine, and nadroparin calcium. After one month of treatment,
a progressive dyspnea appeared, associated to a fever up to 40 C.
Investigations attributed the fever to a purulent sinusitis with
presence of Staphylococcus aureus and Streptococcus pneumoniae.
Apyrexia was obtained with adapted antibiotic therapy and sinus
drainage. Nevertheless the patient still displayed dyspnea.
A Sadoul scale stage II dyspnea was the only symptom detected.
The blood oxygen saturation was of 86% at room air. The chest
examination found bilateral ﬁne crackles. White blood cell count
revealed 7.6 Giga/l elements (6.3 Giga/l neutrophils, 0.15 Giga/l
lymphocytes and normal eosinophil, basophil and monocyte
counts). Plasma ﬁbrinogen concentration was of 9 g/l. Liver
enzymes were elevated (ASAT¼ 2 N, ALAT¼ 2.5 N), and a chole-
stasis was detected (gammaglutamyl transpeptidase and alkaline
phosphatase elevated at 3 N). The renal function was normal.
Chest radiograph showed bilateral interstitial inﬁltrate, and
thoracic computed tomography conﬁrmed by bilateral ground-
glass opacities (Fig. 1). Pulmonary function tests revealed
a moderate restrictive ventilatory defect (TLC 76.5%, RV 79.1% of
predicted values, FEV1/FVC 94.2), and a severe alteration of lung
diffusing capacity (DLCO 38.9% value, DLCO adjusted for alveolar
volume DLCO/AV 64.1% of predicted value).
A bronchoscopy was performed and showed a haemorrhagic
aspect of the bronchial mucosa at the entry of the lower right lobe
Fig. 1. Case no. 1. Thoracic computed tomography: ground-glass aspect.
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analysis of broncho-alveolar lavage (BAL) was negative. BAL ﬂuid
cytologic analysis revealed a proﬁle compatible with hypersensi-
tivity pneumonitis (31% macrophages, 40% lymphocytes with
various activation stages, 29% granulocytes, mainly eosinophils).
Transbronchial lung biopsies conﬁrmed the hypersensitivity
pneumonitis on alveolar lumen containing many macrophages,
lymphocytic inﬁltrate in alveolar septa with a recent ﬁbrosis
including rare endoalveolar buds, and some granulomas.
The dyspnea being well tolerated, no corticosteroid therapy was
required. Everolimus was stopped and the evolutionwas favourable
with improvement of dyspnea and radiological abnormalities.
Diagnosis of everolimus-associated pneumonitis was retained
on the absence of infectious disease, the chronology of the events
and the presence of histological features of hypersensitivity
pneumonitis.Fig. 2. Case no. 2. Thoracic computed tomography: alveolar opacities and bilateral
ground-glass aspect.1.2. Case 2
A 51-year-old patient was referred to the pulmonary depart-
ment because of an interstitial pneumonia, associated with
asthenia, anorexia, weight loss, and fever. His main medical past
was a renal adenocarcinoma with pulmonary metastases already
present at diagnosis in March 2007. A treatment of 10 mg/d of
everolimus was started at that date. Other therapies included par-
acetamol, levocetirizine, and atorvastatine. One month later,
progressive dyspnea with morning dry cough, fever up to 38.5 C,
shivers, weight loss of 2 kg, anorexia and asthenia developed. There
was no thoracic pain, nor extrapulmonary sign to explain this fever.
Chest examination was normal and blood oxygen saturation was of
98% at room air.
Chest radiograph revealed some discrete diffuse alveolar opac-
ities conﬁrmed by thoracic computed tomography, associated to
bilateral ground-glass opacities. Pulmonary function tests showed
a moderate alteration of carbon oxide diffusing capacity (90% of
predicted values) without any ventilatory defect. Bronchoscopy
was macroscopically normal. The extensive microbial analysis of
BAL was negative. BAL ﬂuid cytologic analysis showed again
a proﬁle compatible to hypersensitivity pneumonitis (15% macro-
phages, 77% lymphocytes with a polymorphic lymphoid pop-
ulation, 8% neutrophils). Transbronchial lung biopsies revealed
a hypersensitivity pneumonitis with lymphocytic inﬁltrates on
alveolar septa, eosinophilic granulocytes, a recent ﬁbrosis and some
granulomas.Everolimus was stopped. After one month, pulmonary symp-
toms and fever had disappeared. Thoracic computed tomography
showed the persistence of metastatic lesions but a disappearance of
ground-glass opacities.
We concluded to an everolimus-associated hypersensitivity
pneumonitis because of clinical, radiological and anatomopatho-
logical ﬁndings, and of the clinical evolution.
1.3. Case 3
A 74-year-old patient was admitted in the nephrology depart-
ment because of a feverish dyspnea. He was followed for a chronic
glomerulonephritis since 1976. A ﬁrst renal transplantation was
performed in 1990 and a second in 2002 because of a chronic graft
rejection. The treatment included tacrolimus and mycophenolate
mofetil. This immunosuppressive therapy induced a cutaneous
carcinoma. It was replaced by sirolimus in March 2006, then by
everolimus in August 2006 because of anemia. Everolimus serum
levels were in the therapeutic range, between 8 and 10 mg/l.
In September 2007, the patient displayed cough with feverish
(39 C) dyspnea. A probabilistic antibiotic therapy including
a third-generation cephalosporin was started but failed. Chest
examination found previously known systolic mitral murmur,
diminution of breath sounds in the left pulmonary ﬁeld associated
with ﬁne crackles, and ronchi in right pulmonary base. The blood
oxygen saturationwas of 94% under 2 l/min of oxygen. White blood
cell count was of 4.48 Giga/l. There was an inﬂammatory anemia
with hemoglobin at 7.7 g/dL and a C reactive protein level of
151 mg/L. The renal function was stable with a serum creatinine
level of 146 mmol/l. Liver enzymes were elevated (ASAT¼ 2.5 N,
ALAT¼ 2 N), a cholestasis was detected (gammaglutamyl trans-
ferase at 1.8 N, alkaline phosphatases at 1.5 N).
Chest radiograph revealed alveolar opacities in upper and lower
left lung lobes, and an interstitial syndrome of lower right lobe.
Thoracic computed tomography showed ground-glass and alveolar
opacities in the middle lobe and the upper right lobe, and ground-
glass opacities of both lung bases (Fig. 2). Antibiotic therapy con-
taining ceftriaxone and oﬂoxacin was started without success.
Bronchoscopy was macroscopically normal. The extensive
microbial analysis of BAL and blood cultures was negative. BAL ﬂuid
cytologic analysis found 33% macrophages, 63% lymphocytes with
various activation stages, 1.8% neutrophils and 1% eosinophils,
a proﬁle compatible with a hypersensitivity pneumonitis. Trans-
bronchial lung biopsies conﬁrmed this diagnosis with a recent
ﬁbrosis forming endoalveolar ﬁbrous buds. Antibiotic therapy and
everolimus were discontinued. A corticosteroid therapy at 1 mg/kg
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apyrexia regression of chest symptoms and biological inﬂamma-
tory syndrome.
Diagnosis of everolimus-associated hypersensitivity pneumo-
nitis was retained on the clinical and biological evolution, the
radiological and anatomopathological aspects and the absence of
infectious disease.
2. Discussion
Everolimus is an immunosuppressive therapy inhibiting T and B
lymphocytes proliferation by inactivating mTOR, the mammalian
target of rapamycin. Its mechanism of action is the same as rapa-
mycin or sirolimus. It is used in solid organ transplantation in
complement or as an alternative to calcineurin inhibitors, and its
use increases mainly in cardiac, pulmonary and renal trans-
plantation. It is used as an antineoplastic agent too, in particular to
treat metastatic kidney adenocarcinoma. Its absorption is inﬂu-
enced by feeding intake. Many drug interactions lead to variations
of its serum levels (ﬂuconazole, erythromycin, diltiazem, verap-
amil, ciclosporin increase serum level, rifampicin, phenobarbital,
phenytoin, carbamazepine decrease serum level). Its metabolism
depends on cytochrome CYP 3A4.1
In our three case reports, diagnosis of everolimus-induced
interstitial pneumonitis was made on several elements compatible
with drug-induced hypersensitivity pneumonitis: clinical course,
radiological ﬁndings, cytological proﬁle of BAL, and anatomopa-
thological characteristics. The absence of differential diagnosis,
notably infection, contributed to the diagnosis. One case of ever-
olimus-induced pneumonitis was previously reported by David and
colleagues.2 The clinical presentationwas similar as our cases: a 71-
year-old patient, who received a cardiac graft 19 years ago, treated
by everolimus, mycophenolate mofetil and prednisone, displayed
a progressive dyspnea. Thoracic computed tomography showed an
aspect of bronchiolitis obliterans, and BAL revealed alveolitis with
excessive counts of lymphocytes and neutrophils. The diagnosis
was carried out in a context of high everolimus serum levels.
Evolution was favourable after discontinuation of everolimus,
replaced by ciclosporin, and corticosteroids. Another case of ever-
olimus-associated pneumonitis in a renal transplant recipient was
reported by Alexandru and colleagues.3 The clinical presentation
was: a 57-year-old kidney transplant recipient treated by ever-
olimus and mycophenolate mofetil displayed a progressive dysp-
nea with fever. Everolimus blood levels were in the therapeutic
range (6.5 ng/ml). Thoracic computed tomography showed bilateral
pulmonary inﬁltrates. A BAL revealed lymphocytic inﬁltration
conﬁrmed by the lung biopsy where CD8 cells predominated. The
patient required admission to an intensive care unit. Outcome was
favourable after drug withdrawal and corticosteroid treatment.
Recently, Exposito and colleagues4 described two heart transplant
recipients developing a typical interstitial pneumonitis after ever-
olimus treatment. These authors have shown as well as us that
everolimus discontinuation resulted in rapid clinical and radio-
logical improvements.
Sirolimus-induced hypersensitivity pneumonitis is well
known.5–14 Various types of pulmonary diseases were reported:
sub-acute interstitial pneumonia, desquamative interstitial pneu-
monia, diffuse alveolar damage, granulomatous interstitial pneu-
monia, alveolar haemorrhage, hemolytic uremic syndrome
associated or not with pulmonary hypertension. Champion and
colleagues13 reported 24 cases of drug-induced interstitial pneu-
monitis in a series of 217 renal transplant recipients treated with
sirolimus. Clinical examinations were variable and included
dyspnea, cough, asthenia, haemoptysis, fever, ﬁne crackles and
wheezings. Median duration before respiratory symptomsemerged was 5.5 months after the beginning of the treatment.
Thoracic computed tomography revealed bilateral interstitial
inﬁltrates, reticular opacities with aspect of ground-glass, or
alveolar opacities. BAL analysis showed lymphocytic alveolitis,
eosinophilia, neutrophils, alveolar haemorrhage in two cases, and
no argument for an infectious etiology. Evolution was favorable
after discontinuation of the treatment, either spontaneously, or
after corticosteroid therapy. Clinical symptoms improved, as well
as radiological abnormalities, in all but one case. Clinical, radio-
logical and anatomopathological aspects of sirolimus-induced
pneumonitis are similar to our observations of everolimus-
induced pneumonitis.
Because of BAL ﬁndings and transbronchial lung biopsies, our
three case reports correspond to hypersensitivity pneumonitis
(acute, interstitial sub-acute or granulomatous alveolitis aspect).
The mechanism of everolimus-associated lung toxicity is
therefore probably similar to this of sirolimus-related pneu-
monitis, as both drugs belong to the same class of agents and
act with the same mechanism. An initial treatment by calci-
neurin inhibitor and high drug serum levels could therefore be
relevant risk factors for everolimus-induced pneumonitis as
they are for sirolimus.13 The case reported by David and
colleagues2 is in keeping with this hypothesis. Many new anti-
neoplastic agents have lung toxicity with many clinical mani-
festations and various pathogenesis.15 Several forms of lung
disease were observed with sirolimus and can be expected
under everolimus therapy. A recent publication16 reported 5
cases of sirolimus-induced interstitial pneumonitis in renal
transplant recipients with a favorable evolution after discon-
tinuation and switch to everolimus therapy, started without
recurrence of pneumonitis. However in the context of the
similarity between the drugs and the frequency of pneumonitis
induced by both, it is probably questionable to replace sirolimus
by everolimus in case of pneumonitis. The cases reported here
plead against this attitude.
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